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Be a Target to Guide
Anticoagulation Treatment
in Patients With Low-Risk
Atrial Fibrillation to Reduce
Cognitive Impairment?As commented on by Dr. Ammirati and colleagues, the recent
evidence (1) that the prevalence of silent cerebral ischemia (SCI)
in patients with paroxysmal and persistent atrial ﬁbrillation (AF)
and controls in sinus rhythm implies several clinically relevant
issues.
The ﬁnding that approximately half of the controls presented at
least an area of SCI is strongly hypothesis-generating. In contrast,
the prevalence of other cardioembolic sources, such as patent fo-
ramen ovale or nonstenotic carotid plaques material, should not
be stratiﬁed differently within cases and controls; therefore, not
biasing the main results of the study.
The question of whether SCI represents a target for oral anti-
coagulation (OAC) to prevent cognitive impairment is crucial. Risk
stratiﬁcation, to date, relies on clinical scores (CHA2DS2-VASc
score) based on symptomatic cerebral events only, which is
fallacious.
The occurrence of cerebrovascular events in AF patients, despite
a low-risk score, is unfortunately not unusual (2), and warrantsintroduction of “new” markers, such as left atrial appendage
morphology (3,4) and speciﬁc echocardiographic parameters (5).
Limited literature has assessed whether antiaggregants and/or
OAC may prevent or reduce SCI. One small study (6) suggested
that aspirin attenuates SCI incidence in AF patients, preventing
events in early stages of AF-related cerebral damage, and conse-
quently, cognitive decline. However, this option is not recom-
mended due to the detrimental effects of antiaggregants on
bleeding (7). We fully agree with Ammirati et al. that further
prospective randomized trials are needed to evaluate the possible
reduction of SCI by OAC. In the meantime, aggressive rhythm
control strategy is mandatory to prevent clinical and SCI areas by
restoring and maintaining sinus rhythm.*Fiorenzo Gaita, MD, Prof
Laura Corsinovi, MD, PhD
Matteo Anselmino, MD, PhD
*Cardiology Division
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